Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.

Data published in the Journal of the American Geriatrics Society suggest direct-acting antivirals (DAAs) are safe and effective at achieving a sustained virologic response in older adults with hepatitis C virus (HCV)-related fibrosis or cirrhosis.

HCV clearance is essential in improving disease outcomes in the general population, but data on reducing liver-related complications and increasing life expectancy in older adults are limited.

The researchers concluded that DAAs were safe and improved quality of life and positive clinical outcomes in adults at least 80 years old who have HCV and liver fibrosis or cirrhosis. The effects were especially robust for individuals with <3 comorbidities and normal albumin levels and only marginally effective for those with ≥3 comorbidities and an albumin level of 3.5 g/dL or less. Therefore, the use of DAAs is suggested for those with ≤3 comorbidities and normal serum levels and can be considered for patients in between the 2 extremes reported here.